Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (77)	9/13/2006 8:56:35 AM
From: dr.praveen	Read Replies (2) \| Respond to of 285

Hi Elisabeth, Since the 600mg data didn't show any change in efficacy, It might be a good idea to try the 150mg dose along with the 300mg in the P2B study. There might be a sell off today coz the valuation is a bit high and the 600mg study didn't show a greater efficacy. But OTOH other drugs like Multaq ran into some problems and is being delayed. Mgmt says they don't want to sell the Co. They want to go for a partnership before the large P3 study. All in all the efficacy is solid with the 300mg oral dose with a good safety profile. It increases my confidence in the oral program. But my only concern stopping me from having a big position is how the FDA visualises the old IV RSD1235 data which has less no's. I have already sold my trading shares before these results and I am going to keep my core position. Regards, Praveen